Phase I Clinical Trial of Pembrolizumab + and Denileukin diftitox in Patients with Recurrent Solid Tumors Shows Promising Results

Results from an ongoing investigator-initiated Phase I clinical trial (NCT05200559) evaluating the safety and efficacy of a combined regimen of pembrolizumab* (Keytruda®; Merck & Co/MSD) + denileukin diftitox-cxdl** (E7777; Lymphir™; Citius Oncology) in patients with recurrent solid tumors, shows positive preliminary study results.

Authors

Publication Details

Journal
Onco Zine - The International Oncology Network
Published
2024-11-11
DOI
https://doi.org/10.14229/onco.2024.11.11.002
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase I Clinical Trial of Pembrolizumab + and Denileukin diftitox in Patients with Recurrent Solid Tumors Shows Promising Results

Peter Hofland
Onco Zine - The International Oncology Network
HER2/EGFR in Cancer Research
article

Phase I Clinical Trial of Pembrolizumab + and Denileukin diftitox in Patients with Recurrent Solid Tumors Shows Promising Results

Peter Hofland
article en

Abstract

Results from an ongoing investigator-initiated Phase I clinical trial (NCT05200559) evaluating the safety and efficacy of a combined regimen of pembrolizumab* (Keytruda®; Merck & Co/MSD) + denileukin diftitox-cxdl** (E7777; Lymphir™; Citius Oncology) in patients with recurrent solid tumors, shows positive preliminary study results.

Onco Zine - The International Oncology Network
Good health and well-being
Openalex Percentile: Top 64%
HER2/EGFR in Cancer Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Phase I Clinical Trial of Pembrolizumab + and Denileukin diftitox in Patients with Recurrent Solid Tumors Shows Promising Results — Peter Hofland · Onco Zine - The International Oncology Network (2024) | TGRS Research Map | TGRS